Cutaneous scars resulting from trauma or surgical intervention often cause functional impairment, cosmetic discomfort, and psychological distress. Non-ablative fractional lasers (NAFL) stimulate dermal neocollagenesis while maintaining epidermal integrity. To describe clinical outcomes, tolerability, and changes in measured scar dimensions following high-energy 1470 nm non-ablative fractional diode laser treatment in two patients. Two female patients with Fitzpatrick skin types II and III presented with facial scars following traumatic injury (Patient 1) and surgical lip-lift intervention (Patient 2) were enrolled in this clinical study. Treatments were administered using a 1470 nm diode laser (LaserMe) at high energy fluences (38–40 mJ/point) with tight spot spacing (1.0 mm). Dimensional metrics (length and width) and clinical scores via the Subject Global Aesthetic Improvement Scale (SGAIS) were monitored. At the last reported dimensional assessment (Day 93 in the pooled scar-level table), the glabellar scar decreased in length from 3.2 to 2.0 cm (37.5%) and in width from 6.5 to 3.0 mm (53.8%). The right subnasal scar decreased by 15.4% in length and 25.0% in width; the left subnasal scar decreased by 37.5% in length and 50.0% in width. Both patients were rated much improved (SGAIS = 1). No persistent pigmentary adverse events were reported within the documented observation period. In these two cases, 1470 nm non-ablative fractional diode laser treatment demonstrated potential for scar remodeling with acceptable short-term tolerability. Larger controlled studies with longer follow-up are needed.
Vulvovaginal symptoms may occur outside menopause after obstetric trauma or hormonal changes. A 40-year-old woman presented with vulvar burning and dyspareunia persisting for six years after vaginal delivery, followed by two years of breastfeeding and approximately four years of oral contraception. Examination showed vulvovaginal hypotrophy resembling genitourinary syndrome of menopause and a symptomatic post-obstetric introital deformity with hymenal caruncles. Three monthly injections of non-crosslinked hyaluronic acid with 0.01% calcium hydroxyapatite were administered to the vulva and lower third of the vagina, followed by suture-free en bloc excision of the caruncles using bipolar radiofrequency electrosurgery. The Vaginal Health Index increased from 5 to 20 and 23, the six-item Female Sexual Function Index from 2 to 22 and 30, and dyspareunia visual analog scale scores decreased from 10 to 3 and 0 at three months postoperatively, without complications. This hypothesis-generating case cannot establish that preoperative biostimulation improves surgical outcomes.
Abstract Background: High-frequency ultrasonography has become an essential adjunct in modern aesthetic practice, particularly for improving the safety and accuracy of injectable fillers. While the sonographic appearance of commonly used fillers is well described, limited data exist regarding agarose-based gel fillers. Objective: To describe the immediate in-vivo ultrasound appearance of injectable agarose gel filler in the temple region and to correlate imaging findings with procedural technique and tissue integration. Methods: Two patients undergoing agarose gel filler injection for temporal hollowing were evaluated using real-time, high-frequency ultrasound before and immediately after injection. Results: Agarose gel filler demonstrated a well-defined, predominantly isoechoic appearance with minimal acoustic artifact. Integration with surrounding tissues varied depending on timing and injection dynamics. Conclusion: Agarose-based fillers exhibit a distinct and reproducible sonographic pattern. Ultrasound guidance provides valuable real-time feedback during injection and enhances understanding of filler behavior in vivo.
Poly-D,L-lactic acid (PDLLA) is increasingly used as a collagen-stimulating injectable with a favorable safety profile. However, reports of nodules associated with PDLLA remain limited, particularly in anatomically sensitive areas such as the neck. We report a case of early, asymptomatic cervical nodules occurring after PDLLA injection, characterized clinically and by high-resolution ultrasound. The case is discussed in the context of injection technique, anatomical considerations, and real-world procedural factors that may predispose to product accumulation. This report highlights that early nodules following PDLLA injection may reflect technical deposition rather than inflammatory or granulomatous reactions. Awareness of neck anatomy, careful handling of PDLLA suspensions, and the use of ultrasound can aid in accurate diagnosis and prevention of similar events.
EU regulation requires that cosmetic products be safe and that claims not mislead consumers. It does not require that claims be compositionally grounded. A product marketed as "barrier-restoring" need not contain barrier lipids at any particular concentration. Practitioners who want to check whether formulation composition supports a declared function have no standardised procedure for doing so from the label alone. To develop a structured, label-based methodology - the Multi-Vector Functional Mapping (MVFM) - for analysing cosmetic formulations from their INCI composition without laboratory data or proprietary tools. The MVFM locates the first regulated preservative or fragrance marker in the INCI list and uses its position as a segmentation boundary. Ingredients above that boundary are scored on three functional vectors - Hydration (H), Lipid (L), Structural (S) - on a 0–3 scale. Three commercial products with different declared functions were used as a test case. Segmentation worked without ambiguity in all three products. Products A and C returned vector profiles consistent with their label claims. Product B - marketed as anti-aging - scored H=4, L=7, S=6: a lipid-dominant profile more consistent with a texture-focused cream than with a bioactive-driven anti-aging formula. Two fragrance allergens regulated under Commission Regulation (EU) 2023/1545 were identified in the functional zone of Product B. The MVFM converts the INCI list into a reproducible functional profile. Three products tested by one evaluator show it functions as designed. Larger-scale validation and inter-rater reliability testing remain to be done.
